Tissue plasminogen activator-induced reperfusion injury after stroke revisited

Circulation

Volumn 116, Issue 4, 2007, Pages 363-365

  Hermann, Dirk M ^a   Matter, Christian M ^b,c  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Blood brain barrier; Editorials; Inflammation; Mast cells; Tissue plasminogen activator

Indexed keywords

ACTIVATED PROTEIN C; BASIC FIBROBLAST GROWTH FACTOR; CASPASE 8; CHEMOKINE RECEPTOR CCR3; CHYMASE; CROMOGLYCATE DISODIUM; GELATINASE A; GELATINASE B; HEPARIN; HISTAMINE; HISTAMINE H1 RECEPTOR; HISTAMINE H2 RECEPTOR; HISTIDINE DECARBOXYLASE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; SERINE PROTEINASE; TISSUE PLASMINOGEN ACTIVATOR; TRYPTASE; TUMOR NECROSIS FACTOR ALPHA;

ANTICOAGULANT THERAPY; ARTERY INTIMA PROLIFERATION; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; EDITORIAL; HUMAN; MACROPHAGE; OCCLUSIVE CEREBROVASCULAR DISEASE; PATHOPHYSIOLOGY; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; RECEPTOR BLOCKING; REPERFUSION INJURY; RISK ASSESSMENT; SMOOTH MUSCLE FIBER; STROKE; THROMBOGENESIS; VASCULAR SMOOTH MUSCLE;

CEREBROVASCULAR ACCIDENT; HUMANS; INTRACRANIAL HEMORRHAGES; REPERFUSION INJURY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 34547565191     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.107.712380     Document Type: Editorial

References (20)

1. ATLANTIS, ECASS, and NINDS rtPA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rtPA stroke trials. Lancet. 2004;363:768-774.
2. Hermann DM, Bassetti CL. Implications of ATP-binding cassette transporters for brain pharmacotherapies. Trends Pharmacol Sci. 2007;28:128-134.
3. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med. 2006;354:610-621.
4. Cheng T, Petraglia AL, Li Z, Thiyagarajan M, Zhong Z, Wu Z, Liu D, Maggirwar SB, Deane R, Fernandez JA, LaRue B, Griffin JH, Chopp M, Zlokovic BV. Activated protein C inhibits tissue plasminogen activator-induced brain hemorrhage. Nat Med. 2006;12:1278-1285.
5. Kilic E, Kilic Ü, Reiter RJ, Bassetti CL, Hermann DM. Tissue-plasminogen activator-induced ischemic brain injury is reversed by melatonin: role of iNOS and Akt. J Pineal Res. 2005;39:151-155.
6. Kilic E, Kilic Ü, Matter CM, Lüscher TF, Bassetti CL, Hermann DM. Aggravation of focal cerebral ischemia by tissue plasminogen activator is reversed by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor but does not depend on endothelial NO synthase. Stroke. 2005;36:332-336.
7. Zhang L, Zhang ZG, Ding GL, Jiang Q, Liu X, Meng H, Hozeska A, Zhang C, Li L, Morris D, Zhang RL, Lu M, Chopp M. Multitargeted effects of statin-enhanced thrombolytic therapy for stroke with recombinant human tissue-type plasminogen activator in the rat. Circulation. 2005;112:3486-3494.
8. Liu D, Cheng T, Guo H, Fernandez JA, Griffin JH, Song X, Zlokovic BV. Tissue plasminogen activator neurovascular toxicity is controlled by activated protein C. Nat Med. 2004;10:1379-1383.
9. Verstraete M, Bounameaux H, de Cock F, Van de Werf F, Collen D. Pharmacokinetics and systemic fibrinogenolytic effects of recombinant human tissue-type plasminogen activator (rtPA) in humans. J Pharmacol Exp Ther. 1985;235:506-512.
10. Strbian D, Karjalainen-Lindsberg M-L, Kovanen PT, Tatlisumak T, Lindsberg PJ. Mast cell stabilization reduces hemorrhage formation and mortality after administration of thrombolytics in experimental ischemic stroke. Circulation. 2007;116:411-418.
11. Benoist C, Mathis D. Mast cells in autoimmune disease. Nature. 2002;420:875-878.
12. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685-1695.
13. Kovanen PT, Kaartinen M, Paavonen T. Infiltrates of activated mast cells at the site of coronary atheromatous erosion or rupture in myocardial infarction. Circulation. 1995;92:1084-1088.
14. Abbott NJ. Inflammatory mediators and modulation of blood-brain barrier permeability. Cell Mol Neurobiol. 2000;20:131-147.
15. Steffel J, Akhmedov A, Greutert H, Lüscher TF, Tanner FC. Histamine induces tissue factor expression: implications for acute coronary syndromes. Circulation. 2005;112:341-349.
16. Murata Y, Tanimoto A, Wang KY, Tsutsui M, Sasaguri Y, De Corte F, Matsushita H. Granulocyte macrophage-colony stimulating factor increases the expression of histamine and histamine receptors in monocytes/macrophages in relation to arteriosclerosis. Arterioscler Thromb Vasc Biol. 2005;25:430-435.
17. Sasaguri Y, Wang KY, Tanimoto A, Tsutsui M, Ueno H, Murata Y, Kohno Y, Yamada S, Ohtsu H. Role of histamine produced by bone marrow-derived vascular cells in pathogenesis of atherosclerosis. Circ Res. 2005;96:974-981.
18. Miyazawa N, Watanabe S, Matsuda A, Kondo K, Hashimoto H, Umemura K, Nakashima M. Role of histamine H1 and H2 receptor antagonists in the prevention of intimal thickening. Eur J Pharmacol. 1998;362:53-59.
19. Edelman ER, Adams DH, Karnovsky MJ. Effect of controlled adventitial heparin delivery on smooth muscle cell proliferation following endothelial injury. Proc Natl Acad Sci U S A. 1990;87:3773-3777.
20. Lappalainen H, Laine P, Pentikainen MO, Sajantila A, Kovanen PT. Mast cells in neovascularized human coronary plaques store and secrete basic fibroblast growth factor, a potent angiogenic mediator. Arterioscler Thromb Vasc Biol. 2004;24:1880-1885.